• Beam Therapeutics appointed Eric Foster as chief commercial officer to lead commercial strategy as programs move toward potential launches.
• Foster most recently served as chief commercial officer at Ardelyx.
• He previously led Horizon’s gout and ophthalmology units, overseeing franchises with USD 2.75 billion in net sales.
• Earlier roles included senior vice president and U.S. general manager at Amgen, sales and marketing leadership at GlaxoSmithKline, roles at Johnson & Johnson.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609010700PRIMZONEFULLFEED9818894) on September 01, 2026, and is solely responsible for the information contained therein.